Market Place
Sourcing Support
Upsher Smith`s Generics Deflazacort Receives Approval in US
05 Nov 2024 //
FDA
PTC Therapeutics Reports Q2 2024 Results And Corporate Update
08 Aug 2024 //
PR NEWSWIRE
Cranbury Pharmaceuticals Receives FDA Approval For Generic Emflaza
12 Jun 2024 //
BUSINESSWIRE
PTC`s Emflaza to face generics this month post Aurobindo FDA nod
12 Feb 2024 //
FIERCE PHARMA
Aurobindo Pharma`s Generic Deflazacort Receives Approval in the U.S.
09 Feb 2024 //
FDA
Aurobindo`s Generic Deflazacort Receives Approval in the U.S.
29 Mar 2023 //
FDA
Amber Specialty Pharmacy Selected by PTC Therapeutics, Inc. to Dispense EMFLAZA®
08 Oct 2020 //
BUSINESSWIRE
Sarepta now needs flawless progress for gene therapy
20 Aug 2019 //
BIOPHARMADIVE
Sarepta’s DMD drug hit with FDA Complete Response Letter
20 Aug 2019 //
PHARMA TIMES
Sarepta Duchenne drug rejected by FDA in surprise setback
20 Aug 2019 //
BIOPHARMADIVE
FDA spurns Sarepta’s second Duchenne drug
19 Aug 2019 //
FIERCE BIOTECH
ICER blasts FDA, PTC and Sarepta for high prices on DMD Emflaza, Exondys 51
17 Aug 2019 //
ENDPTS
PTC Therapeutics Receives FDA Approval for Expansion of the EMFLAZA Labeling
08 Jun 2019 //
PR NEWSWIRE
Could Novartis` gene therapy have more than one price?
23 May 2019 //
BIOSPECTRUMASIA
Idorsia sheds surplus DMD therapy to Santhera
21 Nov 2018 //
FIERCE BIOTECH
Clozel hands over a rival to PTC’s controversial steroid deflazacort
20 Nov 2018 //
ENDPTS
Mallinckrodt doses first patient in muscular dystrophy trial
03 Aug 2018 //
PM LIVE
PTC in the hot seat again over price hikes on DMD med Emflaza
20 Jan 2018 //
FIERCE PHARMA
The next Emflaza: Acer Therapeutics looks to take a page out of Marathon’s book
18 Jan 2018 //
ENDPTS
PTC Therapeutics CEO to Fight for DMD Therapy, Pushes Forward with SMA Treatment
11 Jan 2018 //
BIOSPACE
After disappointing 2016, new drug approvals roared back to life in 2017
02 Jan 2018 //
FIERCE BIOTECH
Gottlieb signals priorities for FDA, including drug pricing
31 May 2017 //
POLITICO
New price for muscular dystrophy drug draws criticism
10 May 2017 //
CNBC
How low does DMD med Emflaza`s price need to go? PTC hopes $35,000 is low enough
09 May 2017 //
FIERCE PHARMA
Embattled Marathon Pharma May Shutter Operations by May 1
25 Apr 2017 //
BIOSPACE
The Cost of Drugs for Rare Diseases Is Threatening the U.S. Health Care System
10 Apr 2017 //
HARVARD BUSINESS REVIEW
Sky-High Drug Prices For Rare Diseases Show Why Orphan Drug Act Needs Reform
18 Mar 2017 //
HUFFINGTON POST
Marathon, under heavy fire for Emflaza pricing, makes surprise deal to sell drug
17 Mar 2017 //
FIERCE PHARMA
Eight senators pile on to Marathon`s Emflaza—and its $89,000 pricing blunder
07 Mar 2017 //
FIERCE PHARMA
Senators Ask GAO to Probe Orphan Drug Act as Questions Pile
06 Mar 2017 //
RAPS
CRISPR/Cas9 Startup Exonics Therapeutics Launches in Boston
27 Feb 2017 //
BIOSPACE
First Ariad, Now Senator Bernie Sanders Puts This Drug Company on Notice
16 Feb 2017 //
BIOSPACE
Lawmakers question pricing of drug for genetic disease
14 Feb 2017 //
MEDICAL XPRESS
Why Did That Drug Price Increase 6,000%? It`s The Law
11 Feb 2017 //
FORBES
Another biotech games the system, and everyone gets to pay for the fallout
10 Feb 2017 //
ENDPOINTS
FDA approves drug to treat Duchenne muscular dystrophy
09 Feb 2017 //
PR NEWSIWRE
The `devil is in the details’ of potential U.S. tax changes, pharma execs say
09 Feb 2017 //
FIERCE PHARMA
Marathon hopes to succeed where others have fallen with Duchenne NDA
14 Jun 2016 //
FIERCE BIOTECH
Formulation and evaluation of Deflazacort liquisolid tablets
19 May 2016 //
PHARMA-EXCIPIENTS
Marathon Announces Nationwide Expanded Access Program for Patients with DMD
09 Mar 2016 //
PR NEWSWIRE
